Expand ADCT Menu
ADCT MENU

ADCT Stock Posts


ADCT stock declines -54.2% in premarket,

Premarket Decliner

ADCT Adc Therapeutics SA Common Shares3.08-0.09-2.8%

Premarket:1.41-1.67 (-54.2%)

ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

PRNewswireWed, 3-Jun 4:05 PM
Unusual Option Volume

ADCT Adc Therapeutics SA Common Shares3.71-0.89 (-19.4%)

Adc Therapeutics SA Common Shares trades 30,499 contracts. The company has the following event: Corporate Webcast on Dec 3, 2025. News: ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
View Details...
$ADCT Earnings March 18 BMO. 19-Mar-21 Straddle Implies ±9.7% Move vs Prev. Move -2.0%
Unusual Option Volume

ADCT Adc Therapeutics SA Common Shares32.04+0.44 (+1.4%)

Adc Therapeutics SA Common Shares trades 3,005 contracts. The highest volume is in the 16-Jul-21 35 calls, which is 9.2% above the current price.
View Details...
Load Earlier Posts
Market Data Delayed 15 Minutes